agilon health Valuation

Is AGL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AGL ($2.11) is trading below our estimate of fair value ($12.07)

Significantly Below Fair Value: AGL is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGL?

Key metric: As AGL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AGL. This is calculated by dividing AGL's market cap by their current revenue.
What is AGL's PS Ratio?
PS Ratio0.2x
SalesUS$5.59b
Market CapUS$869.36m

Price to Sales Ratio vs Peers

How does AGL's PS Ratio compare to its peers?

The above table shows the PS ratio for AGL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.3x
CSTL Castle Biosciences
2.7x0.9%US$852.5m
NNOX Nano-X Imaging
34.4x51.0%US$367.5m
DCGO DocGo
0.6x-21.8%US$447.0m
TALK Talkspace
3.2x18.8%US$586.2m
AGL agilon health
0.2x14.2%US$869.4m

Price-To-Sales vs Peers: AGL is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (10.3x).


Price to Sales Ratio vs Industry

How does AGL's PS Ratio compare vs other companies in the US Healthcare Industry?

30 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.1.1x6.6%
AGL agilon health
0.2x14.2%US$869.36m
MCK McKesson
0.2x8.1%US$79.51b
CVS CVS Health
0.2x4.5%US$75.45b
AGL 0.2xIndustry Avg. 1.1xNo. of Companies30PS012345+
30 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.1x21.0%
AGL agilon health
0.2x56.5%US$869.36m
No more companies

Price-To-Sales vs Industry: AGL is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Healthcare industry average (1.1x).


Price to Sales Ratio vs Fair Ratio

What is AGL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: AGL is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AGL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.11
US$3.63
+71.9%
66.5%US$11.00US$1.75n/a15
Nov ’25US$2.70
US$6.22
+130.4%
34.7%US$11.00US$2.50n/a17
Oct ’25US$3.67
US$7.10
+93.5%
25.6%US$11.00US$4.00n/a17
Sep ’25US$4.08
US$7.16
+75.5%
24.6%US$11.00US$4.00n/a17
Aug ’25US$6.57
US$7.22
+9.9%
25.4%US$12.00US$5.00n/a17
Jul ’25US$6.07
US$7.85
+29.3%
44.2%US$20.00US$5.00n/a18
Jun ’25US$6.30
US$7.90
+25.4%
46.2%US$20.00US$5.00n/a18
May ’25US$4.96
US$8.44
+70.2%
44.4%US$20.00US$5.00n/a17
Apr ’25US$5.84
US$8.72
+49.3%
42.9%US$20.00US$5.00n/a16
Mar ’25US$6.04
US$9.17
+51.8%
39.8%US$20.00US$6.00n/a15
Feb ’25US$6.01
US$12.93
+115.2%
35.1%US$25.00US$7.00n/a15
Jan ’25US$12.55
US$19.27
+53.5%
20.0%US$25.00US$12.00n/a15
Dec ’24US$11.28
US$22.00
+95.0%
25.7%US$36.00US$12.00n/a14
Nov ’24US$16.87
US$28.79
+70.6%
17.8%US$41.00US$20.00US$2.7014
Oct ’24US$17.76
US$28.71
+61.7%
17.6%US$41.00US$21.00US$3.6714
Sep ’24US$17.80
US$28.71
+61.3%
17.6%US$41.00US$21.00US$4.0814
Aug ’24US$18.30
US$28.86
+57.7%
17.3%US$41.00US$18.00US$6.5714
Jul ’24US$17.34
US$30.11
+73.6%
14.0%US$41.00US$22.50US$6.0714
Jun ’24US$19.27
US$31.31
+62.5%
12.1%US$41.00US$26.00US$6.3013
May ’24US$24.30
US$30.62
+26.0%
13.2%US$41.00US$26.00US$4.9613
Apr ’24US$23.75
US$30.31
+27.6%
13.1%US$41.00US$26.00US$5.8413
Mar ’24US$21.09
US$28.38
+34.6%
21.0%US$41.00US$21.00US$6.0413
Feb ’24US$22.83
US$28.38
+24.3%
21.0%US$41.00US$21.00US$6.0113
Jan ’24US$16.14
US$29.54
+83.0%
17.8%US$41.00US$22.00US$12.5513
Dec ’23US$18.06
US$30.08
+66.6%
17.0%US$41.00US$22.00US$11.2812
Nov ’23US$19.82
US$32.67
+64.8%
12.6%US$41.00US$26.00US$16.8712

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies